Lv1
48 积分 2024-01-13 加入
FDA approves Merck & Co’s pulmonary arterial hypertension drug sotatercept
1个月前
已完结
Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension
1个月前
已关闭
Discovery, Synthesis, and Biological Evaluation of Novel Quinoline-Based PDE4 Inhibitors with Potent Anti-Chronic Obstructive Pulmonary Disease Activity
1个月前
已完结
Discovery, Optimization, and Evaluation of Novel ANGPTL3 Modulators for the Treatment of Hyperlipidemia
2个月前
已完结
Improvement of pulmonary arterial hypertension, inflammatory response, and epithelium injury by dual activation of cAMP/cGMP pathway in a rat model of monocrotaline-induced pulmonary hypertension
3个月前
已完结
Pulmonary hypertension
3个月前
已完结
Pulmonary hypertension
3个月前
已关闭
Improvement of pulmonary arterial hypertension, inflammatory response, and epithelium injury by dual activation of cAMP/cGMP pathway in a rat model of monocrotaline-induced pulmonary hypertension
3个月前
已完结
A novel phosphodiesterase 4/5 dual-target inhibitor ameliorates neuroinflammation via the NF-κB and JNK pathway
3个月前
已完结
Design, Synthesis, and Biological Evaluation of 3-[4-(2-Hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a Potent, Orally Active, Brain Penetrant Inhibitor of Phosphodiesterase 5 (PDE5)
4个月前
已完结
皖公网安备34019202002308
